GlassScriptPhysician profile
Gnanesh R Patel
NPI 1316238298
$48,945.86
in general payments reported to CMS, 2019-2025
35 companies · $2,857 in 2025
The $2,857 reported for 2025 was more than what 76% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $31K · 2020: $4,418 · 2021: $3,284 · 2022: $2,198 · 2023: $2,390 · 2024: $2,682 · 2025: $2,857.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,703 · Education: $226.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,702.92 |
| Education | $226.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $25,459.13 | 2019-2025 | |
| Ucb, INC. | $11,479.17 | 2019-2025 | Cimzia, Bimzelx |
| Amgen INC. | $2,582.65 | 2019-2025 | Evenity, Enbrel, Tavneos |
| Janssen Biotech, INC. | $2,419.89 | 2019-2025 | Tremfya, Simponi Aria, Remicade |
| Novartis Pharmaceuticals Corporation | $1,118.67 | 2019-2025 | |
| Radius Health, INC. | $732.36 | 2019-2025 | Tymlos |
| Pfizer INC. | $642.12 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $637.26 | 2021-2025 | Saphnelo, Evusheld |
| Glaxosmithkline, LLC. | $446.91 | 2019-2025 | Benlysta |
| Janssen Scientific Affairs, LLC | $408.65 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $407.34 | 2019-2025 | Orencia, Sotyktu |
| Mallinckrodt Hospital Products INC. | $379.28 | 2020-2025 | Acthar |
| Organon LLC | $264.14 | 2022-2025 | Hadlima, Renflexis |
| Lilly USA, LLC | $260.41 | 2019-2022 | |
| Ani Pharmaceuticals, INC. | $237.63 | 2024-2025 | Purified Cortrophin Gel |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $219.41 | 2023-2025 | Cyltezo, Ofev |
| Pacira Therapeutics, INC. | $194.74 | 2019-2020 | |
| Mallinckrodt Enterprises LLC | $159.62 | 2019 | |
| Genentech USA, INC. | $140.34 | 2019-2024 | Actemra |
| Alexion Pharmaceuticals, INC. | $121.35 | 2019-2024 | Strensiq |
| Fresenius Kabi USA, LLC | $100.10 | 2023-2025 | Idacio |
| Sanofi-Aventis U.S. LLC | $85.67 | 2019 | |
| Celgene Corporation | $70.59 | 2019 | |
| Genzyme Corporation | $62.57 | 2020-2023 | |
| Actelion Pharmaceuticals US, INC. | $46.92 | 2023 | Uptravi, Opsumit |
| Ferring Pharmaceuticals INC. | $45.47 | 2019-2020 | |
| Novo Nordisk INC | $44.22 | 2019 | |
| Aurinia Pharma U.S., INC. | $37.75 | 2021 | |
| Cumberland Pharmaceuticals, INC. | $32.90 | 2022 | |
| Sobi, INC | $31.40 | 2025 | |
| Kiniksa Pharmaceuticals International, Plc | $19.13 | 2024 | Arcalyst |
| Merck Sharp & Dohme LLC | $16.24 | 2020 | |
| Horizon Therapeutics Plc | $14.55 | 2020 | |
| Ultragenyx Pharmaceutical INC. | $13.79 | 2019 | |
| Bioventus LLC | $13.49 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gnanesh Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.